Gilde Healthcare, established in 1982 and headquartered in Utrecht, Netherlands, is a leading venture capital firm specializing in the healthcare sector. With over €800 million under management, the firm invests in digital health, diagnostics, medical devices, therapeutics, and healthcare services across Europe and North America. Gilde focuses on growth capital and buyout opportunities, typically investing between €1 million and €40 million per transaction, with a preference for majority or significant minority stakes. The firm seeks to be the lead investor and take a board seat, aiming to exit through IPOs, strategic sales, or private placements. Gilde's portfolio spans various healthcare sub-sectors, with a particular emphasis on cardiology, oncology, and women's health.
Founding Member and General Partner - Healthtech / Therapeutics, Venture and Growth
Jelte Goettsch
Associate
Jasper van Gorp
Managing Partner
Edwin de Graaf
Co-Founder and Managing Partner
Edward Hanlon
Investment Manager
Joep Heldens
Investment Manager
Lara Hilgert
Associate
Karl Hofbauer
Operational Partner
Redmar Koene
Investment Manager
Job Komen
Partner
Kasia Lorek
Associate
Stefan Luzi
Partner
Tristan Maguet
Associate
Pieter van der Meer
Co-Founder and Managing Partner
Rafael Natanek
General Partner, Private Equity
Mika Nishimura
Operational Partner
Geoff Pardo
General Partner - Healthtech, Venture and Growth
Marc Olivier Perret
Managing Partner
Herbert Pinedo
Operational Partner
Marion Pouillard
Associate
Marion Pouillard
Senior Associate, Therapeutics, Venture&Growth
Tom Klein Robbenhaar
Partner, Investment Manager
Boyd Rutten
Investment Director
Robert Stein
Partner, Private Equity
Matthew Vessa
Vice President
Stephan Wachtveitl
Senior Associate
Geoffrey Waters
Operational Partner
Paul West
Operational Partner
Richard Wilmot
Partner, HealthTech Venture and Growth
Sonia Hallen
Investment Manager, Therapeutics, Venture&Growth
Past deals in Austin, TX
MicroTransponder
Series F in 2025
MicroTransponder, Inc. is a medical device company based in Austin, Texas, specializing in the development and commercialization of neurostimulation devices aimed at treating neurological disorders. Founded in 2007, the company focuses on therapies that utilize vagus nerve stimulation to address conditions such as tinnitus, chronic pain, and rehabilitation following strokes. Its flagship product, Vivistim, has received FDA approval for use in ischemic stroke survivors experiencing moderate to severe upper limb impairment. MicroTransponder's innovative approaches, which include paired vagus nerve stimulation and wireless neurostimulation systems, are designed to enhance recovery and improve quality of life for patients facing various neurological challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.